🟢 Neumora Therapeutics is trading 8.61% up in pre-market as XBI ETF gains 2.61%

Neumora Therapeutics is trading at $0.79, up 8.61% in pre-market, with the move appearing primarily linked to broader biotech strength. - No new company-specific announcement, earnings release, clinical update, or analyst action was identified for September 24, 2026. - The XBI ETF was up 2.61% pre-market. - Recent updates, including NMRA-215 toxicology results, are older and do not clearly explain this session’s gain.